Cancer Immunotherapy (Volume 209) (Progress in Molecular Biology and Translational Science, Volume 209) - Hardcover

9780443235344: Cancer Immunotherapy (Volume 209) (Progress in Molecular Biology and Translational Science, Volume 209)

Hardcover

ISBN 10: 0443235341 ISBN 13: 9780443235344

Verlag: Academic Press, 2024

Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highlighting its promise and problems. Chapters in this release include The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy, Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy, Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?, Rational Design of adjuvants boosts cancer vaccines, Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma.

Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment.

Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.

�ber die Autorin bzw. den Autor

David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.

Von der hinteren Coverseite

Immunotherapy of cancer holds tremendous promise as a means to specifically kill tumor cells while sparing normal cells from the non-specific cellular damage caused by chemo- or radiotherapy. Immunotherapy uses the immune system's native self-non-self recognition ability to identify tumor-specific cell surface antigens and then kill the cells bearing them. Much progress has been made and cancer immunotherapy now has achieved some remarkable successes. This volume surveys exciting developments in the field while also highlighting its promise and problems.

��ber diesen Titel� kann sich auf eine andere Ausgabe dieses Titels beziehen.

Verlag: Academic Press
Erscheinungsdatum: 2024
Sprache: Englisch
ISBN 10: 0443235341
ISBN 13: 9780443235344
Einband: Gebundene Ausgabe
Auflage: 1
Anzahl der Seiten: 282
Herausgeber: Teplow David B.
Kontakt zum Hersteller: Academic Press
https://shop.elsevier.com/

230 PARK AVENUE, SUITE 800
NY
NY
10169
USA
Verantwortliche Person: eVatmaster Consulting GmbH
497000000000
contact@evatmaster.com

Bettinastr. 30,60325
Frankfurt am Main
60325
Deutschland